CN110507661A - A kind for the treatment of of allopecia composition - Google Patents
A kind for the treatment of of allopecia composition Download PDFInfo
- Publication number
- CN110507661A CN110507661A CN201910516744.1A CN201910516744A CN110507661A CN 110507661 A CN110507661 A CN 110507661A CN 201910516744 A CN201910516744 A CN 201910516744A CN 110507661 A CN110507661 A CN 110507661A
- Authority
- CN
- China
- Prior art keywords
- treatment
- allopecia
- externally applied
- applied drug
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
The present invention provides a kind for the treatment of of allopecia compositions, it is made of medicine for oral administration and externally applied drug or is individually made of externally applied drug, the medicine for oral administration includes the Finasteride and suitable starch of 0.5-2mg, and the externally applied drug includes the menthol of the minoxidil of 1.0-5.0%, 1%, and surplus is solvent.Implementing technical solution of the present invention, to alopecia, especially heredity alopecia seborrheica, there is significant therapeutic effect by being used cooperatively Finasteride and minoxidil preparation.
Description
Technical field
The present invention relates to hair restorer technical field, in particular to a kind for the treatment of of allopecia composition.
Background technique
The hair normally to fall off is at the hair of catagen and stand-down, grows due to entering catagen and newly entering
The hair of phase is constantly in dynamic equilibrium, therefore can maintain the hair of normal quantity.Pathologic alopecia refers to that hair is abnormal or excessive
Fall off, there are many reason, mainly include androgenetic alopecia, nervous baldness, endocrine alopecia, trophism alopecia, physics
Property alopecia, alopecia of chemical origin, infectious alopecia, symptomatic alopecia, congenital alopecia, seasonal alopecia, wherein further including heredity
Property alopecia seborrheica, heredity alopecia seborrheica be it is simultaneous with Seborrhea, seborrhea, mostly with hereditary base
Cause, male sex hormone are related with mental element.
Currently, one of which is minoxidil, from the 1990s there are mainly two types of the products prevented hair loss on the market
It rises, minoxidil is just used with 2% concentration (no prescription) and 3% and 5% concentration (by prescription) with localized forms.Although
Research has shown that the validity of 5% minoxidil is better than the minoxidil of 2% concentration, but minoxidil is promoting hair regeneration side
The validity in face is lower than 40%.Minoxidil is considered as the local gold standard that can be used for hair growth.Another right and wrong
That male amine, is usually administered orally with 1mg/ days dosage, inhibits the effect of alopecia to reach 90% or so, natural on-off cycles of hair growth increases
Effect reach 65% or so, significant effect, but the health giving quality of controlling of Finasteride remains unchanged for heredity alopecia seborrheica
It is lower.
Summary of the invention
In order to solve the above-mentioned technical problem, a kind for the treatment of of allopecia composition, technical side of the invention are disclosed in the present invention
Case is implemented:
A kind for the treatment of of allopecia composition, is made of medicine for oral administration and externally applied drug or is individually made of externally applied drug, described for oral administration
Medicine includes the Finasteride and suitable starch of 0.5-2mg, the externally applied drug include the minoxidil of 1.0-5.0%, 1% it is thin
Lotus brain, surplus are solvent.The composition is used to reduce alopecia in people's object and/or increases hair regeneration.
Preferably, the Finasteride that the medicine for oral administration is 0.5-2mg and tablet or pill that suitable starch is mixed
Or capsule, the preparation that the externally applied drug is the minoxidil of 1.0-5.0%, 1% menthol and suitable solvent are mixed.
Preferably, the solvent is selected from one or both of alcohol, dimethanol, and the volume fraction of the alcohol is
75%.
Preferably, a kind for the treatment of of allopecia composition above-mentioned, is made of medicine for oral administration and externally applied drug, and the medicine for oral administration includes
The Finasteride of 1mg and suitable starch, the externally applied drug include 2.5% minoxidil, 1% menthol, and surplus is molten
Agent.The composition people's object is male.
Preferably, a kind for the treatment of of allopecia composition above-mentioned, is made of externally applied drug, and the externally applied drug includes 2.5% rice
Promise ground you, 1% menthol, surplus is solvent.The composition people's object is women.
Implement technical solution of the present invention, to alopecia, especially to lose by being used cooperatively Finasteride and minoxidil
Transmissibility alopecia seborrheica has significant therapeutic effect, relative to be used alone Finasteride or minoxidil preparation its about
The health giving quality of controlling of heredity alopecia seborrheica significantly improves.In addition, the application be added in minoxidil preparation menthol at
Point, people can not only be allowed to feel that brain is refrigerant, have the effect of refreshing, sebum secretion can also be inhibited, cooperated with minoxidil,
Alopecia seborrheica can effectively be treated.
Specific embodiment
The technical scheme in the embodiments of the invention will be clearly and completely described below, it is clear that described implementation
Example is only a part of the embodiment of the present invention, instead of all the embodiments.Based on the embodiments of the present invention, this field is common
Technical staff's every other embodiment obtained without creative efforts belongs to the model that the present invention protects
It encloses.
Embodiment 1: patient Tang so-and-so, male, heredity alopecia seborrheica, natural alopecia is fast to form Mediterranean shape, 40 years old
When start to be treated with Finasteride, receiving be Mo Shadong guarantor's method only treat two courses for the treatment of, one the course for the treatment of three months, altogether treat
Six months, alopecia continued, and without effect, abandoned treating.Start to begin to use a kind for the treatment of of allopecia group of the present invention within 48 years old
Object is closed, application method: every night takes the medicine for oral administration containing 1mg Finasteride orally, is combed three times with liquid feeding in alopecia portion in the morning, afternoon and evening
Position puts the externally applied drug containing 2.5% minoxidil on the skin, and after two courses for the treatment of (course for the treatment of 6 months), alopecia stops, and number of hairs is bright
It is aobvious to increase.
Embodiment 2: patient Yin so-and-so, male, heredity alopecia seborrheica starts to begin to use of the present invention one for 46 years old
Kind treatment of allopecia composition, application method: every night takes the medicine for oral administration containing 1mg Finasteride orally, uses add three times in the morning, afternoon and evening
Liquid comb puts the externally applied drug containing 2.5% minoxidil on the skin at alopecia position, and after four courses for the treatment of (course for the treatment of 6 months), alopecia stops
Only, and number of hairs is kept.
Embodiment 3: patient thanks so-and-so, and male, heredity alopecia seborrheica starts to begin to use of the present invention one for 46 years old
Kind treatment of allopecia composition, application method: every night takes the medicine for oral administration containing 1mg Finasteride orally, uses add three times in the morning, afternoon and evening
Liquid comb puts the externally applied drug containing 2.5% minoxidil on the skin at alopecia position, and after course for the treatment of (course for the treatment of 6 months), alopecia stops
Only, after two courses for the treatment of, number of hairs increases.
Embodiment 4: patient Mr. Li, male, heredity alopecia seborrheica have formed Mediterranean shape, and forehead hair is few, and 25
Year starts to begin to use a kind for the treatment of of allopecia composition of the present invention, application method: every night it is for oral administration containing 1mg it is non-that
The medicine for oral administration of male amine is combed three times with liquid feeding put the externally applied drug containing 2.5% minoxidil, a course for the treatment of on the skin at alopecia position in the morning, afternoon and evening
After (course for the treatment of 6 months), alopecia stops, and hair amount starts to increase after two courses for the treatment of.
It should be pointed out that the foregoing is merely illustrative of the preferred embodiments of the present invention, it is not intended to limit the invention, it is all
Within the spirit and principles in the present invention, any modification, equivalent replacement, improvement and so on should be included in guarantor of the invention
Within the scope of shield.
Claims (8)
1. a kind for the treatment of of allopecia composition, which is characterized in that it is made of medicine for oral administration and externally applied drug or is individually made of externally applied drug,
The medicine for oral administration includes the Finasteride and suitable starch of 0.5-2mg, and the externally applied drug includes the minot of 1.0-5.0%
You, 1% menthol, surplus is solvent.
2. a kind for the treatment of of allopecia composition according to claim 1, which is characterized in that the medicine for oral administration is 0.5-2mg's
Tablet or pill or capsule that Finasteride and suitable starch are mixed, the externally applied drug are the minot of 1.0-5.0%
The preparation that you, 1% menthol and suitable solvent are mixed.
3. a kind for the treatment of of allopecia composition according to claim 1, which is characterized in that the solvent is selected from alcohol, diformazan
One or both of alcohol, the volume fraction of the alcohol are 75%.
4. a kind for the treatment of of allopecia composition according to claim 1, which is characterized in that it is made of medicine for oral administration and externally applied drug,
The medicine for oral administration includes the Finasteride and suitable starch of 1mg, the externally applied drug include 2.5% minoxidil, 1% it is thin
Lotus brain, surplus are solvent.
5. a kind for the treatment of of allopecia composition according to claim 1, which is characterized in that be made of externally applied drug, the external application
Medicine includes 2.5% minoxidil, 1% menthol, and surplus is solvent.
6. a kind of according to claim 1, treatment of allopecia composition described in any one of 4,5, is used in people's object reduce
Alopecia and/or increase hair regeneration.
7. a kind for the treatment of of allopecia composition according to claims 4, which is characterized in that people's object is male.
8. a kind for the treatment of of allopecia composition according to claims 5, which is characterized in that people's object is women.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910516744.1A CN110507661A (en) | 2019-06-14 | 2019-06-14 | A kind for the treatment of of allopecia composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910516744.1A CN110507661A (en) | 2019-06-14 | 2019-06-14 | A kind for the treatment of of allopecia composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110507661A true CN110507661A (en) | 2019-11-29 |
Family
ID=68623155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910516744.1A Pending CN110507661A (en) | 2019-06-14 | 2019-06-14 | A kind for the treatment of of allopecia composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110507661A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1450890A (en) * | 2000-08-09 | 2003-10-22 | 法马西雅公司 | Novel compositions of minoxidil |
| CN104161739A (en) * | 2014-08-15 | 2014-11-26 | 武汉人福药业有限责任公司 | Finasteride capsule and preparation method thereof |
| CN104784139A (en) * | 2014-01-17 | 2015-07-22 | 南京瑞尔医药有限公司 | Preparation method of finasteride coating tablet |
| US20160213590A1 (en) * | 2014-05-23 | 2016-07-28 | Triple Hair, Inc. | Compositions for Reducing Hair Loss and/or Increasing Hair Regrowth |
| CN105902553A (en) * | 2016-05-29 | 2016-08-31 | 山东仁和堂药业有限公司 | Compound finasteride tablets and preparation process thereof |
-
2019
- 2019-06-14 CN CN201910516744.1A patent/CN110507661A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1450890A (en) * | 2000-08-09 | 2003-10-22 | 法马西雅公司 | Novel compositions of minoxidil |
| CN104784139A (en) * | 2014-01-17 | 2015-07-22 | 南京瑞尔医药有限公司 | Preparation method of finasteride coating tablet |
| US20160213590A1 (en) * | 2014-05-23 | 2016-07-28 | Triple Hair, Inc. | Compositions for Reducing Hair Loss and/or Increasing Hair Regrowth |
| CN104161739A (en) * | 2014-08-15 | 2014-11-26 | 武汉人福药业有限责任公司 | Finasteride capsule and preparation method thereof |
| CN105902553A (en) * | 2016-05-29 | 2016-08-31 | 山东仁和堂药业有限公司 | Compound finasteride tablets and preparation process thereof |
Non-Patent Citations (7)
| Title |
|---|
| 中国中西医结合学会皮肤性病专业委员会: "《中国中西医结合皮肤性病学术会议论文汇编》", 30 November 2004 * |
| 侯连兵等: "《现代个体化药物新剂型.西药卷》", 30 September 2009, 人民军医出版社 * |
| 李世文等: "《老药新用途》", 31 January 2017, 河南科学技术出版社 * |
| 李继俊: "《妇产科内分泌治疗学》", 31 May 2014, 人民军医出版社 * |
| 杜鑫等: "口服非那雄胺联合米诺地尔搽剂治疗男性雄激素性脱发疗效观察", 《中日友好医院学报》 * |
| 陈勇燕: "米诺地尔与非那雄胺对脱发的疗效观察", 《现代诊断与治疗》 * |
| 陈树新等: "米诺地尔洗剂与非那雄胺合用治疗雄激素性脱发的临床疗效观察", 《国际医药卫生导报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8715714B2 (en) | Uses of rare earth elements for hair improvement | |
| US8883131B2 (en) | Composition for the treatment of hair loss and baldness | |
| CN108938485B (en) | Hair growth liquid for preventing alopecia and preparation method thereof | |
| KR101772574B1 (en) | A cosmetic composition for hair care comprising growth factors, highly stable basic fibroblast growth factor and noggin peptide to promote regeneration and growth of hair follicular cell | |
| WO2016046848A2 (en) | Novel formulation of concentrated natural actives in oil-water microemulsion for hair fall prevention and increase in hair density | |
| JP2010501551A (en) | Use of rare earth elements for hair improvement | |
| CN111228172A (en) | High-efficiency hair loss prevention and hair growth composition | |
| EP0376735A2 (en) | Scalp treatment composition | |
| KR102535575B1 (en) | A cosmetic composition for hair care comprising high stable Fibroblast Growth Factor-9 mutant | |
| KR19990018331A (en) | Hair growth promoting composition | |
| CN110507661A (en) | A kind for the treatment of of allopecia composition | |
| US20080267899A1 (en) | Plant extract composition for hair growth | |
| CN102441006B (en) | A kind of hair-regrowth solution containing chlorine dioxide and preparation and application thereof | |
| KR101659316B1 (en) | Composition for stimulating hair growth and preparation method thereof | |
| KR102612128B1 (en) | A cosmetic composition for hair containing an extract of Spiraea prunifolia | |
| US11571382B1 (en) | Herbal shampoo composition and method for preparing the same | |
| KR20200069711A (en) | Scalp essences for scalp care | |
| CN100457174C (en) | Alopecia treating Chinese medicine preparation | |
| KR20090022224A (en) | Cosmetic composition for scalp protection and trichogenousness | |
| CN106309228A (en) | Toothpaste for night use and preparation method thereof | |
| CN112022868A (en) | Application of gentiopicroside in preventing alopecia and promoting hair growth | |
| JPH11302133A (en) | Cosmetic for scalp and hair | |
| CN114948932B (en) | Use of a composition comprising mulberenone for the preparation of a product for the prevention and treatment of hair loss by acting on the hair follicle tissue | |
| KR20100111640A (en) | Manufacturing method of cosmetic composition for trichogenousness or anti-alopecia | |
| JP2005179334A (en) | Cosmetic composition containing panax ginseng c.a. meyer extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191129 |